Ultragenyx Pharmaceutical Inc. (FRA:UP0)

Ultragenyx Pharmaceutical Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	1,860	1,887	3,750	3,552	3,039	5,040
Market Cap Growth	-53.73%	-49.69%	5.56%	16.88%	-39.70%	-32.68%
Enterprise Value	2,303	2,247	3,855	3,940	2,946	4,557
Last Close Price	18.50	17.00	41.40	43.60	42.20	73.00
PS Ratio	3.24	3.29	6.93	9.04	8.94	16.31
PB Ratio	-29.91	137.08	14.80	14.26	9.21	6.21
P/TBV Ratio	-	-	119.17	60.65	21.95	7.67
EV/Sales Ratio	4.03	3.92	7.12	10.03	8.67	14.75
Debt / Equity Ratio	53.41	53.41	3.47	3.39	2.57	0.43
Net Debt / Equity Ratio	25.73	25.73	0.63	0.57	0.03	-0.66
Net Debt / EBITDA Ratio	-0.83	-0.83	-0.33	-0.29	-0.02	1.64
Net Debt / FCF Ratio	-	-	-0.39	-0.30	-0.02	1.47
Asset Turnover	-	-	0.37	0.29	0.24	0.21
Inventory Turnover	-	-	19.62	22.84	34.15	35.05
Quick Ratio	-	-	2.13	2.32	3.04	4.33
Current Ratio	-	-	2.37	2.61	3.38	4.72
Return on Equity (ROE)	-412.99%	-412.99%	-211.71%	-193.22%	-110.96%	-43.72%
Return on Assets (ROA)	-	-	-22.37%	-23.43%	-26.44%	-14.54%
Return on Capital Employed (ROCE)	-	-	-46.20%	-47.00%	-50.50%	-28.50%
Earnings Yield	-26.33%	-25.96%	-14.66%	-15.45%	-21.78%	-7.92%
FCF Yield	-21.62%	-	-10.86%	-13.22%	-15.29%	-7.18%
Buyback Yield / Dilution	-8.90%	-8.90%	-23.11%	-5.19%	-3.13%	-11.42%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.